伊波拉出血熱藥物和疫苗市場報告：趨勢、預測和競爭分析（至 2031 年）

全球伊波拉出血熱藥物和疫苗市場前景看好，醫院和診所市場以及門診手術中心市場都存在機會。預計到 2031 年全球伊波拉出血熱藥物和疫苗市場規模將達到 2.17 億美元，2025 年至 2031 年的複合年成長率為 28.6%。該市場的主要驅動力是日益嚴重的感染疾病以及政府支持伊波拉研究和伊波拉出血熱治療及疫苗開發的措施。

• Lucintel 預測，在預測期內，薩伊的病毒株類型將出現最高的成長。
• 按地區分類，由於通用感染疾病爆發的發生率不斷增加、先進醫療技術的採用不斷增加以及該地區擁有完善的醫療保健基礎設施，北美將繼續成為最大的地區。

伊波拉出血熱藥物和疫苗市場的策略性成長機會

伊波拉出血熱治療和疫苗市場提供了多種成長機會，特別是在藥物開發、製造和分銷領域。疾病爆發期間對更快、更有效干預的需求正在推動這一市場的發展。以下是按應用程式分類的五個關鍵成長機會：

• 擴展mRNA疫苗平台：伊波拉疫苗研發中採用的mRNA技術是一個主要的擴展領域。 mRNA 技術在 COVID-19 中的成功應用可能有望應用於伊波拉疫苗的生產和分發，這可能會徹底改變疫情應變的局面。
• 高風險地區的本地生產疫苗：在西非等伊波拉出血熱疫情多發地區投資疫苗生產設施可能會帶來巨大的成長。本地生產可以減少對全球供應鏈的依賴，同時縮短反應時間並提高區域的準備和復原力。
• 多病原疫苗的開發：設計能夠預防多種病原體（包括伊波拉病毒感染疾病(EVD)）的免疫原也是一種越來越流行的方法。這將改善針對不同感染疾病的疫苗接種活動的協調，並實現更廣泛和有效的預防。
• 合作推動全球衛生計劃：透過聯合政府、非政府組織和製藥公司，我們可以在全球擴大疫苗研究、開發和交付。此類夥伴關係可以匯集和提供治療病毒性出血熱患者創新抗體介入所需的資源。
• 抗體治療的進展：單株抗體療法作為伊波拉病毒疾病的治療選擇還有很長的路要走，但對於未來的發展和商業性開發來說是一個有吸引力的途徑。抗體療法可以為高風險族群提供即時保護，同時提高已感染者的存活率，並補充疫苗宣傳活動。

透過推動創新、提高製造能力和擴大全球影響力，這些策略成長領域有可能改變伊波拉出血熱治療和疫苗市場的格局。結果很可能是對下一次伊波拉出血熱疫情做出更有力、更有效的應對。

伊波拉出血熱藥物和疫苗市場促進因素和挑戰

多種市場促進因素和挑戰影響伊波拉出血熱藥物和疫苗市場的發展和成長。其中包括技術進步、經濟方面和監管考慮。該市場有五個關鍵促進因素和三個關鍵挑戰：

推動伊波拉出血熱藥物和疫苗市場發展的因素如下：

• 疫苗開發的技術革命：mRNA和病毒載體平台等疫苗技術的進步正在推動開發更有效、更快的伊波拉疫苗。這些進展對於加強世界應對伊波拉出血熱疫情的能力至關重要。
• 增加政府和世界衛生組織的支持：各國政府和世界衛生組織正在大力投資伊波拉出血熱研究和疫苗開發。這種支持對於推進臨床試驗、獲得必要的監管核准以及廣泛分發疫苗至關重要。
• 預防性醫療保健需求增加：對伊波拉出血熱潛在影響的認知不斷提高，帶來了對疫苗等預防措施的需求。這種需求正在推動市場發展，尤其是在易受伊波拉出血熱疫情影響的高風險地區。
• 疫苗生產能力的擴大：市場的主要驅動力之一是全球疫苗生產的擴張，尤其是在非洲。本地生產將使我們能夠更快地做出反應，減少對外部供應的依賴，更容易為未來的疫情做好準備。
• 官民合作關係與協作：公共部門與私部門合作可以促進伊波拉出血熱治療和疫苗市場的創新。此類合作有助於匯集資源、技能和資金，從而加快藥物和疫苗的開發進程。

伊波拉出血熱治療和疫苗市場面臨的挑戰包括：

• 監管障礙和核准延遲：在複雜的監管環境中尋求解決方案可能會很困難，從而導致伊波拉出血熱新藥和疫苗的核准和分發延遲。因此，一旦疫情爆發，這種延誤可能會阻礙國際社會採取應對措施。
• 供應鏈和分銷挑戰：將藥品和疫苗運送到基礎設施薄弱的偏遠地區仍然存在問題。低溫運輸物流和運輸問題可能會阻礙及時獲得救命的治療。
• 疫苗厭惡和公眾認知：由於錯誤訊息和不信任導致的疫苗猶豫阻礙了疫苗接種。必須解決大眾對伊波拉疫苗的認知和接受度問題，疫苗接種宣傳活動才能成功。

伊波拉出血熱藥物和疫苗市場中有效治療方法的開發和分發所固有的複雜性因其關鍵促進因素和挑戰而凸顯。技術創新和全球合作改變了格局，但在這些突破成為現實之前必須克服監管和物流障礙。

目錄

第1章執行摘要

第 2 章全球伊波拉出血熱藥物與疫苗市場：市場動態

• 簡介、背景和分類
• 供應鏈
• 產業促進因素與挑戰

第 3 章 市場趨勢與預測分析（2019-2031）

• 宏觀經濟趨勢（2019-2024）與預測（2025-2031）
• 全球伊波拉出血熱藥物與疫苗市場趨勢（2019-2024 年）及預測（2025-2031 年）
• 全球伊波拉出血熱藥物和疫苗市場（以新藥類型）
  • Zmapp
  • Favipiravir
  • Gs-5734
  • Tkm-Ebola
  • Avi-7537
• 全球伊波拉出血熱藥物和疫苗市場（按疫苗類型）
  • Cad3-Zebov
  • Rvsv-Zebov
  • 其他
• 全球伊波拉出血熱藥物和疫苗市場（按病毒株類型）
  • 薩伊
  • 蘇丹
  • 泰式森林
  • 雷斯頓
  • 本迪布焦病毒
• 全球伊波拉出血熱藥物和疫苗市場（按最終用途分類）
  • 醫院和診所
  • 門診手術中心
  • 其他

第 4 章區域市場趨勢與預測分析（2019-2031 年）

• 全球伊波拉出血熱藥物和疫苗市場（按地區）
• 北美伊波拉出血熱藥物和疫苗市場
• 歐洲伊波拉出血熱藥物和疫苗市場
• 亞太伊波拉出血熱藥物與疫苗市場
• 世界其他地區的伊波拉出血熱藥物和疫苗市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球伊波拉出血熱藥物和疫苗市場按新藥類型分類的成長機會
  • 全球伊波拉出血熱藥物和疫苗市場成長機會（按疫苗類型）
  • 全球伊波拉出血熱藥物和疫苗市場成長機會（按病毒株類型）
  • 全球伊波拉出血熱藥物和疫苗市場成長機會（按最終用途分類）
  • 全球伊波拉出血熱藥物和疫苗市場各區域成長機會
• 全球伊波拉出血熱藥物及疫苗市場新趨勢
• 戰略分析
  • 新產品開發
  • 全球伊波拉出血熱治療及疫苗市場產能擴大
  • 全球伊波拉出血熱藥物和疫苗市場的企業合併
  • 認證和許可

第7章主要企業簡介

• Arbutus Biopharma
• GlaxoSmithKline
• Johnson & Johnson Services
• Hemispherx Biopharma
• BioCryst Pharmaceuticals
• NanoViricides
• NewLink Genetics

The future of the global Ebola drug and vaccine market looks promising with opportunities in the hospital & clinic and ambulatory surgical center markets. The global Ebola drug and vaccine market is expected to reach an estimated $217 million by 2031 with a CAGR of 28.6% from 2025 to 2031. The major drivers for this market are the growing prevalence of infectious diseases and supportive government initiatives toward Ebola research and the development of Ebola drugs and vaccines.

• Lucintel forecasts that, within the strain type category, zaire is expected to witness the highest growth over the forecast period.
• In terms of regions, North America will remain the largest region due to the growing prevalence of zoonotic diseases, the rising adoption of advanced medical technologies, and the presence of well-established healthcare infrastructure in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Ebola Drug and Vaccine Market

The Ebola drug and vaccine market is a fast-changing environment where new technologies, partnerships, and regulatory frameworks are emerging to deal with the virus more effectively. These trends show a growing focus on global health security and innovation. Here are five key trends changing this market:

• Increased Emphasis on mRNA Vaccine Technology: The success of mRNA vaccines in COVID-19 has generated interest in using similar technology against Ebola. Companies are exploring mRNA platforms for faster and better vaccines. This could change how quickly new vaccines come to market during outbreaks.
• Scaling Up Global Vaccine Manufacturing Capacity: There is a strong move to expand vaccine manufacturing capacity globally, especially in Africa, to meet global demand. Local production minimizes dependence on imports and increases response time during outbreaks, improving preparedness and equitable distribution of the vaccine.
• Development of Therapeutic Antibodies: Monoclonal antibodies are being explored as an option for Ebola therapy, implying targeted treatment. This helps fill gaps left by vaccines by offering immediate protection and treatment options, particularly for those already infected or at high risk.
• Strengthening Global Health Partnerships: Public-private partnerships have become common, with government, non-governmental organizations, and pharmaceutical companies collaborating to drive innovation and access. These resources facilitate the mobilization of resources to hasten the development and dissemination of Ebola vaccinations and medications.
• Regulatory Harmonization and Fast-Track Approvals: Regulatory agencies are increasingly working together to harmonize standards and fast-track approvals for Ebola drugs and vaccines. Safe treatments reaching markets faster during emergencies enhance global health response efforts, making this an important trend.

These trends are thus collectively reshaping the Ebola drug and vaccine market, driving innovation, expanding access, and enhancing global preparedness. As they continue to evolve, these trends will likely result in more effective and equitable responses to managing Ebola outbreaks around the world.

Recent Developments in the Ebola Drug and Vaccine Market

The Ebola drug and vaccine market has experienced several significant developments aimed at ensuring global preparedness and response to the virus. These include new drug approvals and strategic alliances, among others. Here are five key developments that have major implications for the market:

• FDA Approval of Inmazeb: As the first-line treatment for Ebola, the FDA has approved Regeneron's Inmazeb, a combination of three monoclonal antibodies. The approval signifies an important milestone toward the provision of effective therapies for infected individuals, potentially lowering death tolls in subsequent outbreaks.
• WHO Prequalification of Johnson & Johnson's Zabdeno/Mvabea: The World Health Organization has prequalified Johnson & Johnson's two-shot Ebola vaccine regimen, known as Zabdeno/Mvabea, for emergency use. This move enhances global uptake of the vaccine, especially in areas with poor healthcare infrastructure, improving preventive measures against Ebola.
• Expansion of Manufacturing Facilities in Africa: Several pharmaceutical firms have announced intentions to establish vaccine manufacturing plants within Africa to increase local production during outbreaks, which will be much faster than relying on foreign suppliers when urgent distribution is needed.
• Strategic Collaboration Between GAVI and CEPI: The partnership between GAVI, The Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations (CEPI) has been strengthened to facilitate the development and equitable distribution of vaccines against Ebola disease. Therefore, this cooperation is essential for rapidly reaching at-risk populations through vaccination interventions.

By improving therapy options while expanding access and upgrading manufacturing capabilities, these developments are expected to have a significant impact on the Ebola drug and vaccine market. Combined, they create conditions for more effective global responses to future outbreaks of Ebola.

Strategic Growth Opportunities for Ebola Drug and Vaccine Market

The Ebola drug and vaccine market has several growth opportunities, particularly in the areas of drug development, manufacturing, and distribution. The demand for faster and more effective interventions during disease outbreaks drives these openings. Here are five significant opportunities for growth by application:

• Expanding mRNA Vaccine Platforms: mRNA technologies used to develop Ebola vaccines represent a major area of expansion. The successful use of mRNA technology during COVID-19 has opened up the possibility of its application in Ebola vaccine production and dissemination, which may be game-changing for responses during outbreaks.
• Locally Produced Vaccines in High-Risk Areas: Investing in vaccine production facilities within regions like West Africa that are prone to Ebola outbreaks can result in massive growth. Local manufacturing reduces reliance on global supply chains while hastening reaction times, thereby improving regional preparedness and resilience.
• Development of Multi-Pathogen Vaccines: One increasingly popular approach involves designing immunogens capable of protecting against multiple pathogens, including Ebola virus disease (EVD). This could improve coordination between immunization efforts targeted at different infectious diseases, offering broader protection with greater efficiency.
• Collaboration for Global Health Initiatives: Collaborations between governments, NGOs, and pharmaceutical companies can scale up vaccine R&D and delivery mechanisms worldwide. Such partnerships can pool the resources needed for innovative measures regarding therapeutic antibodies for treating patients with viral hemorrhagic fever, leading to greater accessibility.
• Progress in Therapeutic Antibody Treatment: Monoclonal antibody therapeutics as treatment options for EVD have a long way to go but still represent an attractive avenue for future developments and commercial exploitation. They can provide immediate protection to high-risk population groups while increasing survival rates among those already infected, complementing vaccination campaigns.

By fostering innovation, increasing manufacturing capabilities, and expanding global reach, these strategic growth areas could change the landscape of the Ebola drug and vaccine market. Consequently, they would likely lead to a much stronger and more effective response to the next outbreak of Ebola.

Ebola Drug and Vaccine Market Driver and Challenges

Several drivers and challenges influence the development and growth of the Ebola drug and vaccine market. These encompass technological advances, economic aspects, and regulatory considerations. There are five major drivers and three key challenges that affect this market.

The factors driving the Ebola drug and vaccine market include:

• Technological Revolution for Vaccine Development: Progress in vaccine technology, such as mRNA or viral vector platforms, has led to faster-acting Ebola vaccines that are more efficient. These developments are vital for enhancing global capacities to manage outbreaks.
• Increasing Government and Global Health Organization Support: Governments and global health organizations are investing heavily in Ebola research and vaccine development. This backing is fundamental for moving clinical trials forward, acquiring necessary approvals from regulators, and ensuring widespread distribution of vaccines.
• Rising Demand for Preventive Healthcare: The rising awareness of Ebola's potential impact has generated demand for preventive measures, such as vaccines. This demand drives the market, especially in high-risk areas where outbreaks of Ebola are more likely.
• Expansion of Vaccine Manufacturing Capabilities: One important driver in the market is the growth of vaccine manufacturing worldwide, particularly across Africa. Localized production provides quicker response times and reduces dependence on external supplies, making it easier to prepare for future outbreaks.
• Public-Private Partnerships and Collaborations: The public sector working jointly with the private sector facilitates access to innovation within the Ebola drug and vaccine market. These collaborations help pool resources, skills, and finances, thereby speeding up drug and vaccine development processes.

Challenges in the Ebola drug and vaccine market include:

• Regulatory Hurdles and Approval Delays: Navigating a complex regulatory landscape can be challenging, resulting in delays in the approval or distribution of new drugs or vaccines against Ebola. Consequently, these delays can hinder international responses to an outbreak.
• Supply Chain and Distribution Challenges: Transporting medicines and vaccines to remote areas lacking sufficient infrastructure remains problematic. Issues related to cold chain logistics and transportation can hinder timely access to life-saving treatments.
• Vaccine Hesitancy and Public Perception: Widespread immunization is impeded by vaccine hesitancy driven by misinformation and mistrust. To ensure successful vaccination campaigns, public perception and acceptance of Ebola vaccines must be addressed.

The complexities inherent in the development and distribution of effective treatments for the Ebola drug and vaccine market are illuminated by its major drivers and challenges. Although technological innovation and global collaboration have transformed this situation, it is necessary to overcome regulatory and logistical impediments for these breakthroughs to become reality.

List of Ebola Drug and Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies Ebola drug and vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the Ebola drug and vaccine companies profiled in this report include-

• Arbutus Biopharma
• GlaxoSmithKline
• Johnson & Johnson Services
• Hemispherx Biopharma
• BioCryst Pharmaceuticals
• NanoViricides
• NewLink Genetics

Ebola Drug and Vaccine by Segment

The study includes a forecast for the global Ebola drug and vaccine market by novel drug type, vaccine type, strain type, end use, and region.

Ebola Drug and Vaccine Market by Novel Drug Type [Analysis by Value from 2019 to 2031]:

• Zmapp
• Favipiravir
• Gs-5734
• Tkm-Ebola
• Avi-7537

Ebola Drug and Vaccine Market by Vaccine Type [Analysis by Value from 2019 to 2031]:

• Cad3-Zebov
• Rvsv-Zebov
• Others

Ebola Drug and Vaccine Market by Strain Type [Analysis by Value from 2019 to 2031]:

• Zaire
• Sudan
• Tai Forest
• Reston
• Bundibugyo Virus

Ebola Drug and Vaccine Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Ebola Drug and Vaccine Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Ebola Drug and Vaccine Market

The Ebola drug and vaccine market has experienced significant advancements driven by global efforts to combat the deadly virus. With ongoing outbreaks and the potential for future epidemics, governments and pharmaceutical companies are intensifying their research and development efforts. This has led to accelerated approvals, increased funding, and the introduction of new therapies and vaccines. Key countries like the United States, China, Germany, India, and Japan are at the forefront of these developments.

• United States: The U.S. has been a leader in Ebola research, with recent developments including FDA approval for the Ervebo vaccine and deployment of monoclonal antibody treatments like Inmazeb. Moreover, the government continues to fund research for next-generation vaccines and therapeutics that will ensure preparedness for potential outbreaks while enhancing global health security.
• China: By partnering with African nations and international organizations, China has increased its focus on Ebola. Recent developments include approval of the Ad5-EBOV vaccine developed by CanSino Biologics, which is part of a broader strategy to enhance its influence in global health matters and support pandemic preparedness initiatives.
• Germany: As part of its commitment to the global healthcare industry, developmental efforts toward Ebola are ongoing. Recent developments involve collaborations with international organizations aimed at developing new vaccine candidates and treatments. Additionally, Germany is supporting African nations by funding them and providing technical assistance to strengthen their healthcare systems and response capacities.
• India: India is emerging as a major manufacturer of Ebola vaccines. Recent developments include Bharat Biotech's efforts to scale up production capabilities to manufacture these vaccines on a large scale. At the same time, the nation's pharmaceutical sector produces generic versions of Ebola treatments, making them more affordable for developing countries.
• Japan: Japan is focused on innovative ways to treat or prevent the spread of Ebola. Recent developments include the discovery of new antiviral drugs and the creation of rapid diagnostic tools. Finally, Japan's commitment to global health is demonstrated through its contributions to international research collaborations and funding for vaccine development.

Features of the Global Ebola Drug and Vaccine Market

Market Size Estimates: Ebola drug and vaccine market size estimation in terms of value ($M).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Ebola drug and vaccine market size by various segments, such as by novel drug type, vaccine type, strain type, end use, and region in terms of ($M).

Regional Analysis: Ebola drug and vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different novel drug types, vaccine types, strain types, end uses, and regions for the Ebola drug and vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the Ebola drug and vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the Ebola drug and vaccine market by novel drug type (zmapp, favipiravir, gs-5734, tkm-Ebola, and avi-7537), vaccine type (cad3-zebov, rvsv-zebov, and others), strain type (zaire, sudan, tai forest, reston, and bundibugyo virus), end use (hospitals & clinics, ambulatory surgical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Ebola Drug and Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Ebola Drug and Vaccine Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Ebola Drug and Vaccine Market by Novel Drug Type
  • 3.3.1: Zmapp
  • 3.3.2: Favipiravir
  • 3.3.3: Gs-5734
  • 3.3.4: Tkm-Ebola
  • 3.3.5: Avi-7537
• 3.4: Global Ebola Drug and Vaccine Market by Vaccine Type
  • 3.4.1: Cad3-Zebov
  • 3.4.2: Rvsv-Zebov
  • 3.4.3: Others
• 3.5: Global Ebola Drug and Vaccine Market by Strain Type
  • 3.5.1: Zaire
  • 3.5.2: Sudan
  • 3.5.3: Tai Forest
  • 3.5.4: Reston
  • 3.5.5: Bundibugyo Virus
• 3.6: Global Ebola Drug and Vaccine Market by End Use
  • 3.6.1: Hospitals & Clinics
  • 3.6.2: Ambulatory Surgical Centers
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Ebola Drug and Vaccine Market by Region
• 4.2: North American Ebola Drug and Vaccine Market
  • 4.2.1: North American Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.2.2: North American Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others
• 4.3: European Ebola Drug and Vaccine Market
  • 4.3.1: European Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.3.2: European Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others
• 4.4: APAC Ebola Drug and Vaccine Market
  • 4.4.1: APAC Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.4.2: APAC Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others
• 4.5: ROW Ebola Drug and Vaccine Market
  • 4.5.1: ROW Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.5.2: ROW Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Novel Drug Type
  • 6.1.2: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Vaccine Type
  • 6.1.3: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Strain Type
  • 6.1.4: Growth Opportunities for the Global Ebola Drug and Vaccine Market by End Use
  • 6.1.5: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Region
• 6.2: Emerging Trends in the Global Ebola Drug and Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Ebola Drug and Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Ebola Drug and Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Arbutus Biopharma
• 7.2: GlaxoSmithKline
• 7.3: Johnson & Johnson Services
• 7.4: Hemispherx Biopharma
• 7.5: BioCryst Pharmaceuticals
• 7.6: NanoViricides
• 7.7: NewLink Genetics